In recent trading session, Akebia Therapeutics Inc. (NASDAQ:AKBA) saw 1.6 million shares changing hands at last check today with its beta currently measuring 0.79. Company’s recent per share price level of $1.12 trading at -$0.04 or -3.48% at last check today assigns it a market valuation of $234.67M. That most recent trading price of AKBA’s stock is at a discount of -121.43% from its 52-week high price of $2.48 and is indicating a premium of 30.36% from its 52-week low price of $0.78. Taking a look at company’s average trading volume volume of 4.93 million if we extend that period to 3-months.
Akebia Therapeutics Inc. (NASDAQ:AKBA) trade information
Upright in the red during last session for losing -3.48%, in the last five days AKBA remained trading in the green while hitting it’s week-highest on Thursday, 06/13/24 when the stock touched $1.12 price level, adding 5.88% to its value on the day. Akebia Therapeutics Inc.’s shares saw a change of -9.71% in year-to-date performance and have moved 4.64% in past 5-day. Akebia Therapeutics Inc. (NASDAQ:AKBA) showed a performance of -8.98% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Akebia Therapeutics Inc. (AKBA) estimates and forecasts
Statistics highlight that Akebia Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 4.64% of value to its shares in past 6 months, showing an annual growth rate of 0.00% while that of industry is 14.30.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 35.46% during past 5 years.
AKBA Dividends
Akebia Therapeutics Inc. is more likely to be releasing its next quarterly report in July and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
